Gorfine et al. [54]
|
Random controlled trial
|
Hemorrhoidectomy
|
DepoFoam Bupivacaine 300 mg compared with 0.9 % sodium chloride
|
Numerical rating score (NRS), AUC 0–72 h
|
Pain intensity scores were significantly decreased in the extended release bupivacaine group versus placebo (141.8 vs. 202.5, P < 0.001).
|
Smoot et al. [55]
|
Random controlled trial
|
Mammoplasty
|
DepoFoam bupivacaine 600 mg compared with bupivacaine HCL 200 mg þ epinephrine 1:200,0000
|
NRS-Activity, AUC 0–72 h
|
No statistical difference between the groups (AUC NRS-A, 441 vs. 468, P 1⁄4 0.3999).
|
Golf et al. [29]
|
Random controlled trial
|
Bunionectomy
|
DepoFoam 120 mg compared to 0.9 % sodium chloride
|
NRS AUC 0–24 h
|
Pain intensity score was significantly decreased in lipid nanoparticle bupivacaine versus control, 123.9 in DepoFoam versus 146 in placebo, P < 0.0005.
|
Bramlett et al. [28]
|
Random controlled trial
|
Total knee arthroplasty
|
DepoFoam bupivacaine (133, 266, 399, and 532 mg) compared to bupivacaine HCl 150 mg with epinephrine 1:200,000
|
NRS-A, AUC 0–96 h
|
No statically significant difference between all DepoFoam groups versus bupivacaine HCl (P > 0.05).
|
Cohen et al. [56]
|
Cohort study
|
Colectomy
|
DepoFoam 366 mg compared with postoperative PCA
|
Total milligrams of opioids consumed after surgery and total cost of hospitalization
|
Mean total amount of postsurgical opioids significantly less in DepoFoam compared to PCA group (57 vs. 115 mg, P 1⁄4 0.025). Average cost of hospitalization significantly less in DepoFoam versus PCA (US$ 8766 vs. US$ 11,850 P 1⁄4 0.027).
|